Abbott (ABT) Rises Higher Than Market: Key Facts

Abbott (ABT) closed at $126.45 in the latest trading session, marking a +1.82% move from the prior day. The stock outpaced the S&P 500's daily gain of 0.64%. At the same time, the Dow added 1.23%, and the tech-heavy Nasdaq gained 0.69%. Shares of the maker of infant formula, medical devices and drugs have depreciated by 0.71% over the course of the past month, underperforming the Medical sector's gain of 0.63%, and the S&P 500's gain of 0.55%.The investment community will be closely monitoring the performance of Abbott in its forthcoming earnings report. It is anticipated that the company will report an EPS of $1.5, marking a 11.94% rise compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $11.79 billion, indicating a 7.48% upward movement from the same quarter last year. For the annual period, the Zacks Consensus Estimates anticipate earnings of $5.15 per share and a revenue of $44.6 billion, signifying shifts of +10.28% and 0%, respectively, from the last year. Investors might also notice recent changes to analyst estimates for Abbott. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. As of now, Abbott holds a Zacks Rank of #4 (Sell). In terms of valuation, Abbott is presently being traded at a Forward P/E ratio of 21.92. This signifies a premium in comparison to the average Forward P/E of 18.91 for its industry. Investors should also note that ABT has a PEG ratio of 2.06 right now. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical - Products was holding an average PEG ratio of 1.7 at yesterday's closing price. The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 164, finds itself in the bottom 34% echelons of all 250+ industries. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions. Zacks' Research Chief Picks Stock Most Likely to "At Least Double"Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.See Our Top Stock to Double (Plus 4 Runners Up) >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks